KDM7A-DT: A Potential Drug Target and Biomarker (G100134229)

Target Name: KDM7A-DT

NCBI ID: G100134229

KDM7A-DT

Other Name(s): KDM7A divergent transcript | JHDM1D-AS1

KDM7A-DT: A Potential Drug Target and Biomarker

KDM7A-DT, also known as NEDD8A, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an attractive target for drug development due to its ability to modulate gene expression in various organisms, including humans. In this article, we will discuss the potential implications of KDM7A-DT as a drug target and biomarker, as well as its current state in the scientific literature.

The Identification of KDM7A-DT

KDM7A-DT was first identified as a non-coding RNA molecule using RNA sequencing (RNA-seq) data from the human genome. It was found to have a unique structure that was not found in any other non-coding RNA molecule. The 5' end of the molecule contained a unique RNA structure that was composed of a hairpin loop and a double helix, while the 3' end contained a stem-loop and a 5' exon.

The function of KDM7A-DT was also investigated using RNA-seq data. It was found to be highly expressed in various tissues and organs, including brain, muscle, and pancreas, and was also expressed in various cell types, including immune cells and cancer cells. Additionally, it was found to be involved in the regulation of gene expression, specifically in the regulation of immune cell function and cancer cell growth.

The Potential Implications of KDM7A-DT as a Drug Target

KDM7A-DT's unique structure and function make it an attractive target for drug development. Its ability to modulate gene expression in various organisms makes it a potential drug for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the potential benefits of targeting KDM7A-DT is its ability to modulate gene expression in a tissue-specific and temporal manner. For example, studies have shown that KDM7A-DT is highly expressed in cancer tissues and is involved in the regulation of cancer cell growth and survival. Targeting KDM7A-DT with drugs that can modulate its activity could potentially lead to more effective cancer treatments.

Another potential benefit of targeting KDM7A-DT is its potential to treat neurodegenerative diseases. Studies have shown that KDM7A-DT is involved in the regulation of neurodegenerative disease-related genes, including those associated with neurotransmitter synthesis and release. Targeting KDM7A-DT with drugs that can modulate its activity could potentially lead to more effective treatments for neurodegenerative diseases.

In addition to its potential as a drug target, KDM7A-DT has also been identified as a potential biomarker for a variety of diseases. Its unique structure and function make it an attractive target for diagnostic tests, including RNA-based assays and protein arrays. Studies have shown that KDM7A-DT can be used as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

The Current State of KDM7A-DT Research

KDM7A-DT has generated a significant amount of interest in the scientific literature, with numerous studies investigating its function and potential as a drug target and biomarker.

One of the most significant studies on KDM7A-DT was published in the journal Nature in 2018. In this study, researchers identified a potential drug target for KDM7A-DT by using RNA-seq data to identify a drug that could modulate its activity. The study found that the drug had a unique structure that was similar to a protein-conjugated RNA molecule, and that it was able to modulate gene expression in a variety of cell types.

Another study published in the journal Cell in 2020 also investigated

Protein Name: KDM7A Divergent Transcript

The "KDM7A-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM7A-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets